tiprankstipranks
Trending News
More News >
Ardent Health Partners, Inc. (ARDT)
NYSE:ARDT
US Market

Ardent Health Partners, Inc. (ARDT) Stock Forecast & Price Target

Compare
99 Followers
See the Price Targets and Ratings of:

ARDT Analyst Ratings

Moderate Buy
13Ratings
Moderate Buy
8 Buy
4 Hold
1 Sell
Based on 13 analysts giving stock ratings to
Ardent
Health Partners, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ARDT Stock 12 Month Forecast

Average Price Target

$13.73
▲(58.00% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Ardent Health Partners, Inc. in the last 3 months. The average price target is $13.73 with a high forecast of $17.00 and a low forecast of $10.00. The average price target represents a 58.00% change from the last price of $8.69.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","18":"$18","9.75":"$9.75","12.5":"$12.5","15.25":"$15.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.73,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,9.75,12.5,15.25,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.83,9.458461538461538,10.086923076923076,10.715384615384615,11.343846153846155,11.972307692307691,12.600769230769231,13.22923076923077,13.857692307692307,14.486153846153845,15.114615384615384,15.743076923076924,16.37153846153846,{"y":17,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.83,9.206923076923077,9.583846153846155,9.96076923076923,10.337692307692308,10.714615384615385,11.091538461538462,11.46846153846154,11.845384615384615,12.222307692307693,12.59923076923077,12.976153846153846,13.353076923076923,{"y":13.73,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.83,8.92,9.01,9.1,9.19,9.28,9.370000000000001,9.46,9.55,9.64,9.73,9.82,9.91,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.08,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.66,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.97,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.41,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.73,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.22,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.67,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.08,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.56,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.79,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.83,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$17.00Average Price Target$13.73Lowest Price Target$10.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on ARDT
Truist Financial
Truist Financial
Buy
Reiterated
01/05/26
Analysts Offer Insights on Healthcare Companies: Caris Life Sciences, Inc. (NASDAQ: CAI) and Ardent Health Partners, Inc. (NYSE: ARDT)
RBC Capital Analyst forecast on ARDT
RBC Capital
RBC Capital
$16$14
Buy
61.10%
Upside
Reiterated
12/19/25
RBC Capital Reaffirms Their Buy Rating on Ardent Health Partners, Inc. (ARDT)
Mizuho Securities Analyst forecast on ARDT
Mizuho Securities
Mizuho Securities
$20$12
Buy
38.09%
Upside
Reiterated
12/18/25
Ardent Health price target lowered to $12 from $20 at MizuhoArdent Health price target lowered to $12 from $20 at Mizuho
UBS
$14.5$14
Buy
61.10%
Upside
Reiterated
12/18/25
Ardent Health price target lowered to $14 from $14.50 at UBSArdent Health price target lowered to $14 from $14.50 at UBS
J.P. Morgan Analyst forecast on ARDT
J.P. Morgan
J.P. Morgan
$15$12
Hold
38.09%
Upside
Reiterated
11/24/25
Ardent Health price target lowered to $12 from $15 at JPMorganArdent Health price target lowered to $12 from $15 at JPMorgan
Guggenheim Analyst forecast on ARDT
Guggenheim
Guggenheim
$18$15
Buy
72.61%
Upside
Reiterated
11/17/25
Ardent Health price target lowered to $15 from $18 at GuggenheimArdent Health price target lowered to $15 from $18 at Guggenheim
KeyBanc
Hold
Downgraded
11/16/25
Cautious Outlook on Ardent Health Partners, Inc. Amidst Uncertainty in Financial Projections and Rising Costs
Goldman Sachs Analyst forecast on ARDT
Goldman Sachs
Goldman Sachs
$19$12
Hold
38.09%
Upside
Reiterated
11/14/25
Ardent Health price target lowered to $12 from $19 at Goldman SachsArdent Health price target lowered to $12 from $19 at Goldman Sachs
Morgan Stanley Analyst forecast on ARDT
Morgan Stanley
Morgan Stanley
$12
Hold
38.09%
Upside
Downgraded
11/14/25
Cautious Hold on Ardent Health Partners Amidst Guidance Cuts and Competitive Disadvantages
Leerink Partners Analyst forecast on ARDT
Leerink Partners
Leerink Partners
$16
Buy
84.12%
Upside
Reiterated
11/14/25
Ardent Health Partners, Inc.: Buy Rating Affirmed Amid Low Valuation and Cost-Saving Potential
Stephens
$17
Buy
95.63%
Upside
Assigned
11/14/25
Stephens Reaffirms Their Buy Rating on Ardent Health Partners, Inc. (ARDT)
Loop Capital Markets Analyst forecast on ARDT
Loop Capital Markets
Loop Capital Markets
$17
Buy
95.63%
Upside
Reiterated
11/14/25
Loop Capital Markets Reaffirms Their Buy Rating on Ardent Health Partners, Inc. (ARDT)
Bank of America Securities Analyst forecast on ARDT
Bank of America Securities
Bank of America Securities
$12$10
Sell
15.07%
Upside
Reiterated
11/13/25
Ardent Health Partners, Inc.: Persisting Financial Challenges Lead to Downgraded Outlook and Underperform Rating
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on ARDT
Truist Financial
Truist Financial
Buy
Reiterated
01/05/26
Analysts Offer Insights on Healthcare Companies: Caris Life Sciences, Inc. (NASDAQ: CAI) and Ardent Health Partners, Inc. (NYSE: ARDT)
RBC Capital Analyst forecast on ARDT
RBC Capital
RBC Capital
$16$14
Buy
61.10%
Upside
Reiterated
12/19/25
RBC Capital Reaffirms Their Buy Rating on Ardent Health Partners, Inc. (ARDT)
Mizuho Securities Analyst forecast on ARDT
Mizuho Securities
Mizuho Securities
$20$12
Buy
38.09%
Upside
Reiterated
12/18/25
Ardent Health price target lowered to $12 from $20 at MizuhoArdent Health price target lowered to $12 from $20 at Mizuho
UBS
$14.5$14
Buy
61.10%
Upside
Reiterated
12/18/25
Ardent Health price target lowered to $14 from $14.50 at UBSArdent Health price target lowered to $14 from $14.50 at UBS
J.P. Morgan Analyst forecast on ARDT
J.P. Morgan
J.P. Morgan
$15$12
Hold
38.09%
Upside
Reiterated
11/24/25
Ardent Health price target lowered to $12 from $15 at JPMorganArdent Health price target lowered to $12 from $15 at JPMorgan
Guggenheim Analyst forecast on ARDT
Guggenheim
Guggenheim
$18$15
Buy
72.61%
Upside
Reiterated
11/17/25
Ardent Health price target lowered to $15 from $18 at GuggenheimArdent Health price target lowered to $15 from $18 at Guggenheim
KeyBanc
Hold
Downgraded
11/16/25
Cautious Outlook on Ardent Health Partners, Inc. Amidst Uncertainty in Financial Projections and Rising Costs
Goldman Sachs Analyst forecast on ARDT
Goldman Sachs
Goldman Sachs
$19$12
Hold
38.09%
Upside
Reiterated
11/14/25
Ardent Health price target lowered to $12 from $19 at Goldman SachsArdent Health price target lowered to $12 from $19 at Goldman Sachs
Morgan Stanley Analyst forecast on ARDT
Morgan Stanley
Morgan Stanley
$12
Hold
38.09%
Upside
Downgraded
11/14/25
Cautious Hold on Ardent Health Partners Amidst Guidance Cuts and Competitive Disadvantages
Leerink Partners Analyst forecast on ARDT
Leerink Partners
Leerink Partners
$16
Buy
84.12%
Upside
Reiterated
11/14/25
Ardent Health Partners, Inc.: Buy Rating Affirmed Amid Low Valuation and Cost-Saving Potential
Stephens
$17
Buy
95.63%
Upside
Assigned
11/14/25
Stephens Reaffirms Their Buy Rating on Ardent Health Partners, Inc. (ARDT)
Loop Capital Markets Analyst forecast on ARDT
Loop Capital Markets
Loop Capital Markets
$17
Buy
95.63%
Upside
Reiterated
11/14/25
Loop Capital Markets Reaffirms Their Buy Rating on Ardent Health Partners, Inc. (ARDT)
Bank of America Securities Analyst forecast on ARDT
Bank of America Securities
Bank of America Securities
$12$10
Sell
15.07%
Upside
Reiterated
11/13/25
Ardent Health Partners, Inc.: Persisting Financial Challenges Lead to Downgraded Outlook and Underperform Rating
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ardent Health Partners, Inc.

3 Months
xxx
Success Rate
5/14 ratings generated profit
36%
Average Return
-7.45%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 35.71% of your transactions generating a profit, with an average return of -7.45% per trade.
1 Year
Ben HendrixRBC Capital
Success Rate
1/11 ratings generated profit
9%
Average Return
-25.38%
reiterated a buy rating 28 days ago
Copying Ben Hendrix's trades and holding each position for 1 Year would result in 9.09% of your transactions generating a profit, with an average return of -25.38% per trade.
2 Years
xxx
Success Rate
1/11 ratings generated profit
9%
Average Return
-32.65%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 9.09% of your transactions generating a profit, with an average return of -32.65% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ARDT Analyst Recommendation Trends

Rating
Sep 25
Oct 25
Nov 25
Dec 25
Jan 26
Strong Buy
8
7
10
10
10
Buy
27
28
22
12
4
Hold
15
14
27
26
24
Sell
2
1
1
1
1
Strong Sell
0
0
0
0
0
total
52
50
60
49
39
In the current month, ARDT has received 14 Buy Ratings, 24 Hold Ratings, and 1 Sell Ratings. ARDT average Analyst price target in the past 3 months is 13.73.
Each month's total comprises the sum of three months' worth of ratings.

ARDT Financial Forecast

ARDT Earnings Forecast

Next quarter’s earnings estimate for ARDT is $0.32 with a range of $0.21 to $0.41. The previous quarter’s EPS was -$0.17. ARDT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ARDT has Performed in-line its overall industry.
Next quarter’s earnings estimate for ARDT is $0.32 with a range of $0.21 to $0.41. The previous quarter’s EPS was -$0.17. ARDT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ARDT has Performed in-line its overall industry.

ARDT Sales Forecast

Next quarter’s sales forecast for ARDT is $1.63B with a range of $1.60B to $1.68B. The previous quarter’s sales results were $1.58B. ARDT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ARDT has Performed in-line its overall industry.
Next quarter’s sales forecast for ARDT is $1.63B with a range of $1.60B to $1.68B. The previous quarter’s sales results were $1.58B. ARDT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ARDT has Performed in-line its overall industry.

ARDT Stock Forecast FAQ

What is ARDT’s average 12-month price target, according to analysts?
Based on analyst ratings, Ardent Health Partners, Inc.’s 12-month average price target is 13.73.
    What is ARDT’s upside potential, based on the analysts’ average price target?
    Ardent Health Partners, Inc. has 58.00% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ARDT a Buy, Sell or Hold?
          Ardent Health Partners, Inc. has a consensus rating of Moderate Buy which is based on 8 buy ratings, 4 hold ratings and 1 sell ratings.
            What is Ardent Health Partners, Inc.’s price target?
            The average price target for Ardent Health Partners, Inc. is 13.73. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $17.00 ,the lowest forecast is $10.00. The average price target represents 58.00% Increase from the current price of $8.69.
              What do analysts say about Ardent Health Partners, Inc.?
              Ardent Health Partners, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of ARDT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.